- ACOG has recently released new guidelines on the management of gynecologic issues in women with breast cancer.
Health Awareness Topics - March 2012
New clinican and consumer guidelines
! Visit the AHRQ Evidence Reports
page for a listing of reports produced under AHRQ's Evidence-based Practice Program
and Effective Health Care Program
G-I-N North America Webinar
G-I-N North America
is offering a free Webinar on March 29, 2012 at 1 pm (Pacific)/4 pm (Eastern)
on the topic: AHRQ and NGC Approach to Addressing the IOM Standards: Implications for the North American Guideline Development Community
. Vivian Coates, Project Director of the National Guideline Clearinghouse/National Quality Measures Clearinghouse and Vice President of ECRI Institute, and Jean Slutsky, Director of the Center for Outcomes and Evidence at the Agency for Healthcare Research and Quality, will discuss their phased approach to the IOM Standards for Trustworthy Guidelines. They are also interested in feedback from members of the North American guideline community on how to best meet their needs as end users of the NGC. For more information contact: firstname.lastname@example.org
, 1-510-414-7760, or 1-925-980-5951.
The Guidelines International Network (G-I-N) Conference 2012
, will be held August 22-25, 2012
in Berlin, Germany. Registration
is now open.
U.S. Food and Drug Administration (FDA) Advisories
- March 1, 2012: Statins and HIV or Hepatitis C Drugs : FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy). The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.
- February 28, 2012: Statin Drugs : FDA has approved important safety label changes for the class of cholesterol-lowering drugs known as statins. The changes include removal of routine monitoring of liver enzymes from drug labels. Information about the potential for generally non-serious and reversible cognitive side effects and reports of increased blood sugar and glycosylated hemoglobin (HbA1c) levels has been added to labels.
NGC's Sister Resources